Fate Therapeutics wins $15 million CIRM grant for FT819 lupus nephritis Phase 2 trial
FATE•Fate Therapeutics won a $15 million California Institute for Regenerative Medicine grant to advance its RECLAIM-LN Phase 2 trial of FT819 for refractory lupus nephritis.
1. Grant supports trial
The CLIN2 grant will support Phase 2, potentially registrational testing of FT819, an off-the-shelf CAR T-cell therapy, in refractory lupus nephritis.
